SPECIALTY GUIDELINE MANAGEMENT

PROLIA (denosumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications
   1. Treatment of postmenopausal women with osteoporosis at high risk for fracture
   2. Treatment to increase bone mass in men with osteoporosis at high risk for fracture
   3. Treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture
   4. Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer
   5. Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

B. Compendial Uses
   1. Prevention or treatment of osteoporosis during androgen deprivation therapy for prostate cancer in patients with high fracture risk
   2. Consider in postmenopausal patients receiving adjuvant endocrine therapy along with calcium and vitamin D supplementation to maintain or improve bone mineral density and reduce risk of fractures

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: Supporting chart notes or medical record indicating a history of fractures, T-score, and FRAX fracture probability as applicable to Sections III.A, III.B, and III.C.

III. CRITERIA FOR INITIAL APPROVAL

A. Postmenopausal osteoporosis
   Authorization of 12 months may be granted to postmenopausal members with osteoporosis when ANY of the following criteria are met:
   1. Member has a history of fragility fractures
   2. Member has a pre-treatment T-score less than or equal to -2.5 OR member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability (See Appendix B) and meets ANY of the following criteria:
a. Member has indicators of higher fracture risk (e.g., advanced age, frailty, glucocorticoid use, very low T-scores [less than or equal to -3.5], or increased fall risk)
b. Member has failed prior treatment with or is intolerant to previous injectable osteoporosis therapy (e.g., zoledronic acid [Reclast], teriparatide [Forteo, Bonsity])
c. Member has had an oral bisphosphonate trial of at least 1-year duration or there is a clinical reason to avoid treatment with an oral bisphosphonate (See Appendix A)

B. Osteoporosis in men
Authorization of 12 months may be granted to male members with osteoporosis when ANY of the following criteria are met:
1. Member has a history of an osteoporotic vertebral or hip fracture
2. Member meets criteria BOTH of the following criteria:
   a. Member has a pre-treatment T-score less than or equal to -2.5 OR member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability (See Appendix B)
   b. Member has had an oral OR injectable bisphosphonate trial of at least 1-year duration OR there is a clinical reason to avoid treatment with a bisphosphonate (See Appendix A)

C. Glucocorticoid-induced osteoporosis
Authorization of 12 months may be granted to members with glucocorticoid-induced osteoporosis when ALL of the following criteria are met:
1. Member is currently receiving or will be initiating glucocorticoid therapy
2. Member has had an oral OR injectable bisphosphonate trial of at least 1-year duration OR there is a clinical reason to avoid treatment with a bisphosphonate (See Appendix A)
3. Member meets ANY of the following criteria:
   a. Member has a history of a fragility fracture
   b. Member has a pre-treatment T-score less than or equal to -2.5
   c. Member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability (See Appendix B)

D. Breast cancer
Authorization of 12 months may be granted to members who are receiving adjuvant aromatase inhibitor therapy for breast cancer.

E. Prostate cancer
Authorization of 12 months may be granted to members who are receiving androgen deprivation therapy for prostate cancer.

IV. CONTINUATION OF THERAPY
Authorization of 12 months may be granted for all members (including new members) who are currently receiving the requested medication through a paid pharmacy or medical benefit, and experiences clinical benefit after at least 12 months of therapy with Prolia as evidenced by improvement or stabilization in T-score.

V. APPENDIX
Appendix A. Clinical reasons to avoid oral bisphosphonate therapy
• Esophageal abnormality that delays emptying such as stricture or achalasia
• Active upper gastrointestinal problem (e.g., dysphagia, gastritis, duodenitis, erosive esophagitis, ulcers)
• Inability to stand or sit upright for at least 30 to 60 minutes
• Inability to take at least 30 to 60 minutes before first food, drink, or medication of the day
• Renal insufficiency (creatinine clearance <35 mL/min)
• History of intolerance to an oral bisphosphonate

Appendix B. WHO Fracture Risk Assessment Tool
• High FRAX fracture probability: 10 year major osteoporotic fracture risk ≥ 20% or hip fracture risk ≥ 3%.
• 10-year probability; calculation tool available at: https://www.sheffield.ac.uk/FRAX/
• The estimated risk score generated with FRAX should be multiplied by 1.15 for major osteoporotic fracture and 1.2 for hip fracture if glucocorticoid treatment is greater than 7.5 mg (prednisone equivalent) per day.

VI. REFERENCES